JUL 13, 2017 6:25 PM PDT

Preliminary Approval Issued for Personalized Cancer Therapy

WRITTEN BY: Carmen Leitch

A committee of experts appointed by the Food and Drug Administration (FDA) has approved an experimental personalized therapy, in a first for the United States. In a clinical trial of patients suffering from severe cases of acute lymphoblastic leukemia (ALL), 83 percent of them were free of cancer after three months. Final approval, expected from the FDA on October 3, could be life-changing for those suffering from ALL. 

Bone marrow smear (large magnification) from a patient with acute lymphoblastic leukemia / Credit: WikimediaCommons/Furfur

The treatment, called CTL019, harvests a patient’s white blood cells and genetically reprograms them so that they will become cancer-fighting machines. Specifically, after being removed from the patient, T cells are engineered to express a receptor that will recognize a particular antigen that is indicative of cancerous cells. A patient's natural defense mechanisms can now be used against cancer.

"The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO of Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review."

This particular treatment was developed by Novartis, although other companies are making their forays into this area. Kita Pharma is awaiting their own approval decision on November 29. The video below explains more about this milestone.

Novartis worked with Penn University to create this treatment, which could be a new avenue for kids facing limited options. ALL is responsible for around 25 percent of all childhood cancer diagnoses. For patients that experience multiple relapses, the five-year disease-free survival rate drops to around 20 percent.

"It is encouraging to see the FDA panel's recommendation and continued momentum behind this innovative therapy, which has potential to help young patients with relapsed/refractory B-cell ALL," said the Penn team's leader, Carl June, MD, the Richard W. Vague Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine and Director of the Parker Institute for Cancer Immunotherapy at Penn. "We look forward to continuing to work with Novartis to help make a lasting impact on the way this disease is treated."

"We know firsthand from treating children and young adults with relapsed/refractory B-cell ALL that they desperately need innovative medicines that provide a new approach to managing this aggressive disease," said Stephan Grupp, MD, PhD, the Yetta Deitch Novotny Professor of Pediatrics at the Perelman School of Medicine at Penn, Director of the Cancer Immunotherapy Frontier Program and Chief of the Section of Cellular Therapy and Transplant at CHOP. "Today's vote in favor of CTL019 is a positive step, and we appreciate Novartis' commitment to pediatric patients."

 

Sources: STAT News, Novartis

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 28, 2019
Genetics & Genomics
NOV 28, 2019
Promising New Treatment for Mitochondrial Disease Found in Fruit Flies
Researchers at the University of Cambridge have discovered a protein in fruit flies that can reverse the effects of harmful mutations in mitochondrial gene...
DEC 04, 2019
Cell & Molecular Biology
DEC 04, 2019
Scientists Reverse Cognitive Defects in Down Syndrome Mouse Model
Researchers have found a drug that can correct the memory and learning impairments that are linked to Down syndrome....
DEC 15, 2019
Microbiology
DEC 15, 2019
Potential Therapeutics for Nipah Virus Are Identified
The fatality rate of Nipah virus has an estimated range of 40 to 75 percent...
JAN 04, 2020
Cell & Molecular Biology
JAN 04, 2020
Shared Mechanisms of Mitochondrial Division Highlight Evolutionary Links
Organisms as different as humans and algae have some biological mechanisms in common....
JAN 23, 2020
Cell & Molecular Biology
JAN 23, 2020
Scientists Engineer Venom-Producing Organoids
Snake venom is also a source of therapeutics, and a potential source of new medicines....
FEB 02, 2020
Cell & Molecular Biology
FEB 02, 2020
New T Cell Therapy is a Universal Approach to Target Cancer
For years, researchers have been trying to harness the power of the assassins of the immune system - killer T cells....
Loading Comments...